Clinical Trial Detail

NCT ID NCT02658097
Title A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.